Business Wire

SONIO

20.12.2022 09:31:44 CET | Business Wire | Press release

Share
French Startup Sonio raises €10M through the European Innovation Council Accelerator to improve the health of women and children through AI

Sonio announces a €10M fundraising through the European Innovation Council Accelerator, the leading fund in supporting European deep-tech companies. For this cohort, among 1092 projects submitted, only 78 companies were selected by the EIC Accelerator. This fundraising (€2.5M in grant and €7.5M in equity investment) comes in addition to the €5M previously raised with Elaia, OneRagtime and Bpi France in June 2022. It will support Sonio, a company that empowers fetal medicine professionals and secures pregnancy ultrasounds through AI, to accelerate the release of new features on the platform, such as embedded image recognition and genomics. A great opportunity, also, to gain momentum for the French startup’s market entry in the USA, as well as ramp up sales in Europe and India.

Sonio brings together unique expertise from the fields of fetal medicine, artificial intelligence, software development and ultrasound imaging to address the 50% of congenital malformations that are not detected before birth and improve access and quality of care for pregnant women and children. Created only a couple of years ago, the startup company leverages 5 years of R&D and clinical development at Ecole Polytechnique, the PRAIRIE Institute and Necker Hospital in Paris. It already provides a comprehensive solution to assist all fetal ultrasound practitioners, from beginners to the most seasoned experts and is already being used by over 250 healthcare professionals.

Receiving such a significant funding from one of the most competitive accelerators in the world is a testament to the innovation Sonio brings to fetal medicine” said Cécile Brosset, Chief Executive Officer and co-Founder of Sonio. « Our hard work has been fruitful. I am now more confident than ever that we can help secure pregnancy care worldwide with collective and artificial intelligence.”

“For us this funding means more research, more clinical studies, more innovation, more patents filed in Europe and ultimately an improved quality of care for patients, wherever they are. We are eager to intensify our scientific partnerships with some of the best experts in Fetal Medicine and Artificial Intelligence.” said Rémi Besson, Chief Scientific Officer and co-Founder of Sonio.

Inspired by the company’s mission and in just 2.5 years, Sonio’s multidisciplinary team has already brought 2 products to market:

  • Sonio Diagnostics, designed for expert diagnostic ultrasounds, was CE marked and found its first clients in record time.
  • Sonio Pro, tailored to secure and bring more efficiency to routine pregnancy ultrasounds, was launched in October and has already convinced customers in Europe.

Several partnerships have already been signed, with Samsung France, one of the main women’s health ultrasound manufacturers, but also with specialized distributors (Lifecell in India, Manager Systems in Brazil, Dynamic Medicals in Nigeria).

“This funding from EIC will allow us to accelerate our commercial development in the USA and in Europe, thanks to faster innovation and better market access. We will also be able to initiate more distribution partnerships in countries where access to healthcare is scarce, thus helping us to fulfill our mission, which is to improve access and quality of care of women and children.” said Dagmar Nuber, Chief Business Officer and co-Founder at Sonio.

About Sonio

Founded in 2020, Sonio is the only SaaS platform that empowers healthcare professionals to secure prenatal care by combining technological innovation, medical expertise, and collective intelligence. It provides a unique Artificial Intelligence software that associates the knowledge of prenatal medicine practitioners with all types of medical, imaging, genetic and environmental data to optimize prenatal screening and diagnosis.

Created by a team of entrepreneurs, and scientific, medical and tech experts, Sonio is already used by over 250 healthcare professionals.

Sonio is committed to become an “Entreprise à Mission” – a company whose objectives in the social, societal, and environmental fields are aligned with this purpose and set out in its by-laws, as defined by the 2019 PACTE law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005108/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aarhus Vand Selects Netmore for Smart Meter Network25.8.2026 08:00:00 CEST | Press release

Partnership between Netmore, Aarhus Vand, and Kamstrup supports digitalization of metering network and water conservation across Aarhus Municipality, Denmark Netmore Group, the leading network operator and platform provider for Massive IoT, today announced a collaboration with Aarhus Vand and Kamstrup to support the deployment of approximately 69,000 digitally connected water meters across Aarhus Municipality, Denmark. Powered by Netmore's carrier-grade LoRaWAN® network and Kamstrup's digital water metering technology, the project will provide Aarhus Vand with real-time visibility into water consumption while helping residents better understand and reduce their water usage. Rollout begins in Tranbjerg following a successful pilot involving approximately 1,000 households, where the communication between Kamstrup's digital meters and Aarhus Vand was validated. The full deployment will continue through 2030, covering communities across Aarhus Municipality. The new water meters will elimin

Motorola Solutions fuldfører opkøbet af D-Fend Solutions25.8.2026 08:00:00 CEST | Pressemeddelelse

Beskyttelse af luftrummet for beredskabsmyndigheder og kritisk infrastruktur med differentieret, ikke-kinetisk RF-teknologi til cyberovertagelse Motorola Solutions (NYSE: MSI) har gennemført opkøbet af D-Fend Solutions (D-Fend), der er en førende virksomhed inden for anti-drone-teknologi, for en købspris på 1,5 mia. USD. Handlen giver beredskaber og erhvervsliv adgang til avancerede systemer til bekæmpelse af ubemandede luftfartøjer (C-UAS), der er udviklet til sikkert at neutralisere trusler fra uautoriserede droner. "Sikkerhed på jorden kræver sikkerhed i luften," siger Greg Brown, der er bestyrelsesformand og CEO i Motorola Solutions. "D-Fends gennemprøvede anti-drone-teknologi er et stærkt supplement til vores beredskabsløsninger og giver vores kunder verden over en differentieret beskyttelse af luftrummet." Præcis trusselsbegrænsning I modsætning til traditionelle anti-drone-metoder, der baserer sig på simpel detektion efterfulgt af jamming eller nedskydning, identificerer D-Fends

IFF Report Finds GLP-1 Is Reshaping Food Choices and Eating Behaviors Among Indian Consumers25.8.2026 07:30:00 CEST | Press release

Research highlights emerging opportunities for food and beverage innovation IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — released new research examining how GLP-1 use is influencing food behaviors among Indian consumers and what those shifts may mean for the future of food and beverage innovation. The study is the latest in IFF’s GLP-1 global consumer insights following the company’s 2025 GLP-1 Consumer Opportunity Outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824816059/en/ “We are seeing that a change in appetite can lead to a broader change in the relationship people have with food, from how much consumers eat to how they choose, experience and participate in eating occasions,” said Harsch Koshti, regional marketing director, IFF Taste for Greater Asia. “For the food industry, this is a critical opportunity to listen closely to these emerging behaviors and think about h

Tigo Energy and Ingeteam Sign Certificate of Compatibility25.8.2026 06:00:00 CEST | Press release

Successful testing between Tigo MLPE and Ingeteam inverters validates an open ecosystem with proven compatibility for European solar installers. Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy solutions, today announced a Certificate of Compatibility with European energy technology leader, Ingeteam S.A., documenting which Ingeteam inverters and Tigo Flex MLPE products have passed compatibility testing. The certificate covers certain single-phase and three-phase INGECON® SUN products and members of the Tigo TS4 MLPE product family, when properly designed and installed. Together, these products are designed to deliver high-quality, enhanced value with a system that can generate and manage solar energy more efficiently and provide the features that solar energy customers in the residential, Commercial and Industrial (C&I) and Utility segments demand. Ingeteam, a leading decarbonization and energy transformation company building a sustainable future thr

Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 00:40:00 CEST | Press release

Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-endOmlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentationsMultiple dose strengths and device options broaden treatment flexibility for healthcare professionals Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye